Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: reich hn. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Anti-PLA2R Antibody Levels and Clinical Risk Factors for Treatment Nonresponse in Membranous Nephropathy.
Barbour SJ, Fervenza FC, Induruwage D, Brenchley PE, Rovin B, Hladunewich MA, Reich HN, Lafayette R, Aslam N, Appel GB, Zand L, Kiryluk K, Liu L, Cattran DC; MENTOR Trial Investigators. Barbour SJ, et al. Among authors: reich hn. Clin J Am Soc Nephrol. 2023 Oct 1;18(10):1283-1293. doi: 10.2215/CJN.0000000000000237. Epub 2023 Jul 20. Clin J Am Soc Nephrol. 2023. PMID: 37471101
Phase 2 Trial of Cemdisiran in Adult Patients with IgA Nephropathy: A Randomized Controlled Trial.
Barratt J, Liew A, Yeo SC, Fernström A, Barbour SJ, Sperati CJ, Villanueva R, Wu MJ, Wang D, Borodovsky A, Badri P, Yureneva E, Bhan I, Cattran D; Cemdisiran Phase 2 Study Investigators and Collaborators. Barratt J, et al. Clin J Am Soc Nephrol. 2024 Apr 1;19(4):452-462. doi: 10.2215/CJN.0000000000000384. Epub 2024 Jan 15. Clin J Am Soc Nephrol. 2024. PMID: 38214599 Clinical Trial.
Focal Segmental Glomerulosclerosis: Assessing the Risk of Relapse.
Troyanov S, Jauhal A, Reich HN, Hladunewich MA, Cattran DC; Toronto Glomerulonephritis Registry Group. Troyanov S, et al. Among authors: reich hn. Kidney Int Rep. 2023 Sep 9;8(11):2403-2415. doi: 10.1016/j.ekir.2023.08.035. eCollection 2023 Nov. Kidney Int Rep. 2023. PMID: 38025232 Free PMC article.
PROTECTing the kidneys in IgA nephropathy.
Reich HN, Barbour SJ. Reich HN, et al. Lancet. 2023 Dec 2;402(10417):2046-2047. doi: 10.1016/S0140-6736(23)02418-2. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931627 No abstract available.
Prophylactic Anticoagulation in Nephrotic Syndrome.
Gerstein J, Battu K, Reich HN. Gerstein J, et al. Among authors: reich hn. Kidney360. 2023 Oct 1;4(10):1476-1478. doi: 10.34067/KID.0000000000000225. Kidney360. 2023. PMID: 37526679 Free PMC article. No abstract available.
Dynamics of urine proteomics biomarker and disease progression in patients with IgA nephropathy.
Peters B, Beige J, Siwy J, Rudnicki M, Wendt R, Ortiz A, Sanz AB, Mischak H, Reich HN, Nasic S, Mahmood D, Persson A, Fernström A, Weiner M, Stegmayr B; PersTIgAN Working Group. Peters B, et al. Among authors: reich hn. Nephrol Dial Transplant. 2023 Nov 30;38(12):2826-2834. doi: 10.1093/ndt/gfad125. Nephrol Dial Transplant. 2023. PMID: 37349951 Free PMC article.
IgA nephropathy: the lectin pathway and implications for targeted therapy.
Barratt J, Lafayette RA, Zhang H, Tesar V, Rovin BH, Tumlin JA, Reich HN, Floege J. Barratt J, et al. Among authors: reich hn. Kidney Int. 2023 Aug;104(2):254-264. doi: 10.1016/j.kint.2023.04.029. Epub 2023 May 30. Kidney Int. 2023. PMID: 37263354 Free article. Review.
CanVasc consensus recommendations for the use of avacopan in antineutrophil cytoplasm antibody-associated vasculitis: 2022 addendum.
Turgeon D, Bakowsky V, Baldwin C, Cabral DA, Clements-Baker M, Clifford A, Cohen Tervaert JW, Dehghan N, Ennis D, Famorca L, Fifi-Mah A, Girard LP, Lefebvre F, Liang P, Makhzoum JP, Massicotte-Azarniouch D, Mendel A, Milman N, Reich HN, Robinson DB, Ross C, Rumsey DG, Soowamber M, Towheed TE, Trudeau J, Twilt M, Yacyshyn E, Yardimci GK, Khalidi N, Barra L, Pagnoux C. Turgeon D, et al. Among authors: reich hn. Rheumatology (Oxford). 2023 Aug 1;62(8):2646-2651. doi: 10.1093/rheumatology/kead087. Rheumatology (Oxford). 2023. PMID: 36805625
117 results